Browse NPNT

Summary
SymbolNPNT
Namenephronectin
Aliases EGFL6L; POEM; preosteoblast EGF-like repeat protein with MAM domain; Protein EGFL6-like
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted, extracellular space, extracellular matrix Note=Trapped on the cell surface or in the extracellular matrix.
Domain PF07645 Calcium-binding EGF domain
PF00629 MAM domain
Function

Functional ligand of integrin alpha-8/beta-1 in kidney development. Regulates the expression of GDNF with integrin alpha-8/beta-1 which is essential for kidney development. May also play a role in the development and function of various tissues, regulating cell adhesion, spreading and survival through the binding of several integrins (By similarity).

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001655 urogenital system development
GO:0001657 ureteric bud development
GO:0001658 branching involved in ureteric bud morphogenesis
GO:0001763 morphogenesis of a branching structure
GO:0001822 kidney development
GO:0001823 mesonephros development
GO:0003012 muscle system process
GO:0006936 muscle contraction
GO:0006937 regulation of muscle contraction
GO:0006939 smooth muscle contraction
GO:0006940 regulation of smooth muscle contraction
GO:0007160 cell-matrix adhesion
GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0007179 transforming growth factor beta receptor signaling pathway
GO:0010692 regulation of alkaline phosphatase activity
GO:0010694 positive regulation of alkaline phosphatase activity
GO:0010810 regulation of cell-substrate adhesion
GO:0010811 positive regulation of cell-substrate adhesion
GO:0010921 regulation of phosphatase activity
GO:0010922 positive regulation of phosphatase activity
GO:0016311 dephosphorylation
GO:0017015 regulation of transforming growth factor beta receptor signaling pathway
GO:0030198 extracellular matrix organization
GO:0030278 regulation of ossification
GO:0030511 positive regulation of transforming growth factor beta receptor signaling pathway
GO:0031589 cell-substrate adhesion
GO:0033627 cell adhesion mediated by integrin
GO:0033631 cell-cell adhesion mediated by integrin
GO:0034612 response to tumor necrosis factor
GO:0035239 tube morphogenesis
GO:0035303 regulation of dephosphorylation
GO:0035306 positive regulation of dephosphorylation
GO:0042692 muscle cell differentiation
GO:0043062 extracellular structure organization
GO:0043410 positive regulation of MAPK cascade
GO:0044057 regulation of system process
GO:0045667 regulation of osteoblast differentiation
GO:0045669 positive regulation of osteoblast differentiation
GO:0045778 positive regulation of ossification
GO:0045785 positive regulation of cell adhesion
GO:0045933 positive regulation of muscle contraction
GO:0045987 positive regulation of smooth muscle contraction
GO:0048754 branching morphogenesis of an epithelial tube
GO:0051145 smooth muscle cell differentiation
GO:0060004 reflex
GO:0060562 epithelial tube morphogenesis
GO:0060675 ureteric bud morphogenesis
GO:0060993 kidney morphogenesis
GO:0061138 morphogenesis of a branching epithelium
GO:0061326 renal tubule development
GO:0061333 renal tubule morphogenesis
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
GO:0070374 positive regulation of ERK1 and ERK2 cascade
GO:0071356 cellular response to tumor necrosis factor
GO:0071559 response to transforming growth factor beta
GO:0071560 cellular response to transforming growth factor beta stimulus
GO:0072001 renal system development
GO:0072006 nephron development
GO:0072009 nephron epithelium development
GO:0072028 nephron morphogenesis
GO:0072073 kidney epithelium development
GO:0072078 nephron tubule morphogenesis
GO:0072080 nephron tubule development
GO:0072088 nephron epithelium morphogenesis
GO:0072163 mesonephric epithelium development
GO:0072164 mesonephric tubule development
GO:0072171 mesonephric tubule morphogenesis
GO:0090092 regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090100 positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway
GO:0090257 regulation of muscle system process
GO:0090287 regulation of cellular response to growth factor stimulus
GO:0097195 pilomotor reflex
GO:1903844 regulation of cellular response to transforming growth factor beta stimulus
GO:1903846 positive regulation of cellular response to transforming growth factor beta stimulus
GO:2000721 positive regulation of transcription from RNA polymerase II promoter involved in smooth muscle cell differentiation
Molecular Function GO:0005178 integrin binding
GO:0050839 cell adhesion molecule binding
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005604 basement membrane
GO:0008305 integrin complex
GO:0030485 smooth muscle contractile fiber
GO:0034678 integrin alpha8-beta1 complex
GO:0043235 receptor complex
GO:0043292 contractile fiber
GO:0044420 extracellular matrix component
GO:0044449 contractile fiber part
GO:0098636 protein complex involved in cell adhesion
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolNPNT
Namenephronectin
Aliases EGFL6L; POEM; preosteoblast EGF-like repeat protein with MAM domain; Protein EGFL6-like
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NPNT and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolNPNT
Namenephronectin
Aliases EGFL6L; POEM; preosteoblast EGF-like repeat protein with MAM domain; Protein EGFL6-like
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NPNT in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolNPNT
Namenephronectin
Aliases EGFL6L; POEM; preosteoblast EGF-like repeat protein with MAM domain; Protein EGFL6-like
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NPNT in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9990.0181
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.8380.00878
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.3950.562
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8290.0582
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6530.67
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.0510.584
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.1790.703
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.510.575
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0990.914
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.1410.938
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3660.882
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0310.872
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NPNT in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.49.16.31
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.57.7-3.21
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolNPNT
Namenephronectin
Aliases EGFL6L; POEM; preosteoblast EGF-like repeat protein with MAM domain; Protein EGFL6-like
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NPNT. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNPNT
Namenephronectin
Aliases EGFL6L; POEM; preosteoblast EGF-like repeat protein with MAM domain; Protein EGFL6-like
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NPNT. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NPNT.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNPNT
Namenephronectin
Aliases EGFL6L; POEM; preosteoblast EGF-like repeat protein with MAM domain; Protein EGFL6-like
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NPNT. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNPNT
Namenephronectin
Aliases EGFL6L; POEM; preosteoblast EGF-like repeat protein with MAM domain; Protein EGFL6-like
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NPNT expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNPNT
Namenephronectin
Aliases EGFL6L; POEM; preosteoblast EGF-like repeat protein with MAM domain; Protein EGFL6-like
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NPNT and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNPNT
Namenephronectin
Aliases EGFL6L; POEM; preosteoblast EGF-like repeat protein with MAM domain; Protein EGFL6-like
Chromosomal Location4q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NPNT collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.